Anti-tumor vaccine for the treatment of ovarian cancer.

Abagovomab is an anti-idiotype antibody, able to mimick a tumor antigen highly expressed by ovarian cancer cells.
Abagovomab has the potential to prevent or delay the tumor relapse in patients who responded to the first line chemotherapy by activating an immune response toward cancer cells.

Abagovomab obtained the “Orphan Drug” status by the EMEA and FDA (USA).

The pivotal Phase II/III clinical study, named MIMOSA (www.mimosa-study.com), started in December 2006.
Patients recruitment was completed as expected in December 2008.